Outgoing Ironwood CEO Mark Mallon

Mark Mal­lon wraps a short stint as CEO of Iron­wood, jump­ing out to pur­sue 'mul­ti­ple pas­sion­s' in the wake of set­backs

Mark Mal­lon built his ca­reer over a 24-year stretch at As­traZeneca. But he man­aged less than 2 years as CEO of Iron­wood.

Iron­wood an­nounced Mon­day af­ter­noon that Mal­lon is step­ping down, quot­ing him as en­thused about the chance to sat­is­fy “mul­ti­ple pas­sions” as he head­ed off in pur­suit of a new lead­er­ship post. The biotech’s stock was up 13% ahead of the bell Tues­day.

Pres­i­dent Tom Mc­Court was bumped to the in­ter­im CEO role dur­ing the re­cruit­ment phase for the next CEO and the board chair, Julie McHugh, will help steer the com­pa­ny as ex­ec­u­tive chair­man.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.